

**The American Journal of Human Genetics, Volume 110**


**Supplemental information**

**Efficient *in vivo* prime editing corrects the most  
frequent phenylketonuria variant, associated  
with high unmet medical need**

**Dominique L. Brooks, Madelynn N. Whittaker, Ping Qu, Kiran Musunuru, Rebecca C. Ahrens-Nicklas, and Xiao Wang**


**Figure S1. Scheme for Generation of Humanized R408W Mice.**

**Wildtype Locus of the Murine Pah Gene (standard project)**




blue boxes: murine exons

**Wildtype Locus of the Human Pah Gene (standard project)**




pink boxes: human exons

**Gene Targeted Locus of the Pah Gene (standard project)**



blue boxes: mouse exons; pink boxes: human exons; neo: neomycin cassette for selection in ES cells; loxP: recognition sequence for cre recombinase mediated neo removal


**Gene Targeted Locus after cre mediated neo removal (included in project)**




### Figure S2. Phenylketonuria Phenotypes in Humanized R408W Mice.

(A) Homozygous R408W mouse with PKU as evidenced by hypopigmentation of the fur, on left, compared to heterozygous R408W non-PKU littermate, on right.

(B) Blood phenylalanine levels and weights of homozygous R408W PKU ( $n = 8$  animals) and heterozygous R408W non-PKU ( $n = 6$  animals) age-matched (6 weeks of age) colony-mates. Lines = mean values.  $P$  values calculated with Mann-Whitney  $U$  test.




**Figure S3. Scheme for Generation of Humanized 1066 Mice.**



### Figure S4. Schematic of Dual-AAV Prime Editing System.

PE3 = prime editor 3; AAV = adeno-associated virus; SpPE2 max = *Streptococcus pyogenes* prime editor 2 max; ITR = inverted terminal repeat; Cbh promoter = chicken  $\beta$ -actin promoter with cytomegalovirus early enhancer element; SpCas9max = *Streptococcus pyogenes* Cas9 max; Npu-N = *Nostoc punctiforme* N-terminal split intein; Npu-C = *Nostoc punctiforme* C-terminal split intein; MMLV = Moloney murine leukemia virus; RT = reverse transcriptase; RNaseH = ribonuclease H; SV40 = simian virus 40; pA = polyadenylation signal; mU6 = mouse U6 promoter; sgRNA = single guide RNA; hU6 = human U6 promoter; epegRNA = engineered prime editing guide RNA. This figure was reproduced without changes from reference 16 [Davis, J.R., Banskota, S., Levy, J.M., Newby, G.A., Wang, X., Anzalone, A.V., Nelson, A.T., Chen, P.J., Hennes, A.D., An, M., et al. (2023). Efficient prime editing in mouse brain, liver and heart with dual AAVs. *Nat. Biotechnol.* 10.1038/s41587-023-01758-z] in accordance with the terms of the Creative Commons Attribution 4.0 International License: <https://creativecommons.org/licenses/by/4.0/>.




**Figure S5. Liver Function Tests in Treated PKU and Control Non-PKU Groups of Mice, Related to Figure 5.**

(A) Blood aspartate aminotransferase (AST) levels and alanine aminotransferase (ALT) levels in homozygous PKU mice following treatment with  $8 \times 10^{11}$  vg AAV dose ( $n = 4$  animals) or with  $4 \times 10^{11}$  vg AAV dose ( $n = 3$  animals), comparing levels at various timepoints up to 5 weeks following treatment to levels in untreated heterozygous non-PKU control ( $n = 3$  animals) age-matched (6 weeks of age) colonymates (1 blood sample per timepoint).

(B) AST levels and ALT levels in homozygous PKU mice following treatment with  $8 \times 10^{11}$  vg AAV dose ( $n = 3$  animals), comparing levels at various timepoints up to 5 weeks following treatment to levels in untreated heterozygous non-PKU control ( $n = 2$  animals) age-matched (10 weeks of age) colonymates (1 blood sample per timepoint).

(C) AST levels and ALT levels in compound heterozygous PKU mice following treatment with  $1 \times 10^{12}$  vg AAV dose ( $n = 3$  animals), comparing levels at various timepoints up to 5 weeks following treatment to levels in untreated heterozygous non-PKU control ( $n = 2$  animals) age-matched (6 weeks of age) colonymates (1 blood sample per timepoint).  
Lines in graphs = mean values.





P40	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>CUGAGAAGGGu</b> <b>CggGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P41	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>ACUGAGAAGGGu</b> <b>CggGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P42	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>AACUGAGAAGGGu</b> <b>CggGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P43	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>GAAUCUGAGAAGGGu</b> <b>CggGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P44	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>CGAACUGAGAAGGGu</b> <b>CggGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P45	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>ACUGAGAAaGGu</b> <b>CggGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P46	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>AACUGAGAAaGGu</b> <b>CggGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P47	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>GAAUCUGAGAaGGu</b> <b>CggGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P48	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>CGAACUGAGAAaGGu</b> <b>CggGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P49	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>GAGAAGGGu</b> <b>CgcGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P50	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>GAGAAGGGu</b> <b>CguGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P51	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>GAGAAGGGg</b> <b>CggGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P52	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>GAGAAGGGg</b> <b>CgcGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P53	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>GAGAAGGGg</b> <b>CguGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P54	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>GAGAAGGGa</b> <b>CggGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P55	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>GAGAAGGGa</b> <b>CgcGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>
P56	<b>ACUUUGCUGCCACAAUACCUGUUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUUCAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC</b> <b>GAGAAGGGa</b> <b>CguGGUAUUGUGGCA</b> <b>CGCGGUUCUAUCUAGUUACGCGUUAACCAACUAGAA</b>

Black bold = spacer sequence; red bold = RTT; blue bold = PBS; lower case indicates nucleotide substitution to be introduced by RTT.



**Table S2. ngRNAs.**

N1	<b>UGAGAAGGGCCaAGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N2	<b>UAGCGAACUCUGAGAAGGGCCa</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N3	<b>UGAGAAGGGCCgAGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N4	<b>UGAGAAGGGGuCgAGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N5	<b>UGAGAAGGGGuCggGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N6	<b>UGAGAAaGGuCgAGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N7	<b>UGAGAAaGGuCggGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N8	<b>ACUUUGCUGCCACAAUACC</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N9	<b>ACUUUGCUGCCACAAUACCc</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N10	<b>ACUUUGCUGCCACAAUgCCc</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N11	<b>ACUUUGCUGCCACgAUgCCc</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N12	<b>UGAGAAGGGGuCgcGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N13	<b>UGAGAAGGGGuCguGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N14	<b>UGAGAAGGGGgCggGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N15	<b>UGAGAAGGGGgCgcGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N16	<b>UGAGAAGGGGgCguGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N17	<b>UGAGAAGGGGaCggGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N18	<b>UGAGAAGGGGaCgcGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
N19	<b>UGAGAAGGGGaCguGGUAUUG</b> GUUUUAGAGCUAGAAAUAGCAAGUUAUUAAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU

Black bold = spacer sequence; lower case indicates position complementary to nucleotide substitution introduced by RTT.



**Table S4. Assessment of Off-target Editing in R408W Homozygous HuH-7 Cells.**

Genomic site	Protospacer/PAM sequence <sup>a</sup>	Amplicon (chromosome: position range) <sup>b</sup>	Treated sample 1 <sup>c</sup>	Treated sample 2	Treated sample 3	Control sample 1	Control sample 2	Control sample 3
PAH	ACTTTGCTGCCACAATACCTTGG	chr12:102840439-102840600	32.32	29.99	32.40			
OT1	ttTaTGCTGCCA-AATACCTAGG	chr8:78462251-78462495	0.62	0.47	0.48	0.55	0.60	0.57
OT2	AagcgtgTGCACAATACCTGGG	chr2:13589808+13589996	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT3	tCTaTGCTGCCA-AATACCTGGG	chr4:169715128-169715285	0.95	0.61	0.66	0.59	0.75	0.89
OT4	AaTcTaCTGCCA-AATACCTGGG	chr8:76707015-76707213	0.43	0.39	0.45	0.41	0.48	0.47
OT5	AggTTG-TaCCACAATACCTTGG	chr10:113490901-113491091	0.51	0.51	0.48	0.49	0.50	0.45
OT6	AgcTgGCTG-CACAATACCTTGG	chr13:56216964-56217162	0.55	0.43	0.47	0.50	0.44	0.47
OT7	tCTgcGgTGCACAATACCTTGG	chr12:98762684+98762848	0.59	0.61	0.56	0.75	0.52	0.71
OT8	AgagTGCaGcCACAAATACCTAGG	chr9:28448755+28448930	0.71	0.73	0.67	0.64	0.72	0.68
OT9	ACaaTaCTGCCA-AATACCTAGG	chr6:45052043-45052196	0.71	0.64	0.78	1.53	0.78	1.39
OT10	AtTTATGaaGCCACAATACCTGGG	chr12:90309031+90309183	0.67	0.64	0.58	0.64	0.67	0.61
OT11	gtTTTGCTGCCACAAGACCTAGG	chr6:46216177-46216276	0.86	0.64	0.46	0.43	0.59	0.51
OT12	tgTTTGTGCCA-AATACCTTGG	chr7:136729999-136730159	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT13	ACTTcaCTGCCatAATACCTGGG	chr2:195824652-195824785	0.95	0.78	1.11	0.89	0.81	0.84
OT14	ACTTTatATGaCAAAATACCTGGG	chr9:117378303+117378482	0.48	0.54	0.39	0.54	0.61	0.47
OT15	tCTcTGCT-CCACAATACCTAGG	chr3:25365542+25365698	0.50	0.44	0.47	0.52	0.45	0.55
OT16	tCTgTGCTGCC-CAATACCTTGG	chr13:35884818+35884996	0.72	0.56	0.60	0.64	0.66	0.52
OT17	cCTcTtCT-CCACAATACCTAGG	chr21:27362728-27362863	0.80	0.64	0.62	0.65	0.79	0.66
OT18	gCTTTCCTGCCAC-ATACCTGGG	chr1:84363379+84363574	0.55	0.56	0.57	0.47	0.57	0.47
OT19	Ag-aTGCTGCaCAAAATACCTAGG	chr18:3456273-3456460	0.80	0.54	0.61	0.62	0.54	0.55
OT20	AggTTcCTcCCACAATACCTGGG	chr5:2961395+2961503	0.70	0.61	0.62	0.78	0.76	0.72
OT21	ACTTTGCaGCCACATACCTGGG	chr17:61009795+61009954	0.67	0.72	0.83	0.84	n.d.	1.22
OT22	A-TgTgATcCCACAATACCTGGG	chr12:5650929-5651072	0.54	0.63	0.64	0.66	0.60	0.56
OT23	AtTcT-TCTGCCatAATACCTGGG	chr8:108304580-108304753	0.52	0.56	0.65	1.10	0.48	0.61
OT24	cCTTTGCTcCCTCAATACCTAGG	chr12:53011957-53012129	0.70	0.62	0.66	0.61	0.71	0.58
OT25	ACTTTGCaGCCACatgACCTGGG	chr17:75547288+75547430	0.56	0.53	0.78	0.69	0.58	0.63
OT26	ACTTTGCTtCCAaAATAgCTGGG	chr13:76387376-76387540	0.69	0.59	0.62	0.71	0.65	0.70
OT27	ACTTTGtTtCCACAATAgCTAGG	chr13:77055944-77056107	0.69	0.61	0.74	1.11	0.54	0.65
OT28	ACTTTGCTGCTcACAATcCCTAGC	chr13:81974451+81974555	0.40	0.49	0.52	0.39	0.51	0.51
OT29	ACTTTGtTGCCACAgACCTGGG	chr10:73226422+73226613	0.82	0.68	0.99	0.73	0.73	0.88
OT30	ACaTTGTcACACAATACCTAGT	chr11:1493022+1493184	0.72	0.71	0.64	0.65	0.69	0.64
OT31	AaTTTGCTGaCACAAGACCTTGG	chr11:10677426+10677544	0.50	0.59	0.35	0.46	0.47	0.53
OT32	AgTTTGCTtCCACAATAcATAGG	chr11:36513516+36513638	0.59	0.52	0.64	0.56	0.51	0.51
OT33	taTTTGCTGCCAgAATACCTTGG	chr9:73068606-73068772	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT34	ACagTGCTGCCAAaAATACCTGGG	chr15:78935858+78935995	0.62	0.64	0.77	0.61	0.52	0.63
OT35	ACTTgcCTGCCAcAATACCTGGG	chrY:7231179+7231337	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT36	ACTTTGATGCCACAATAtCaTGG	chr7:24649482-24649678	0.64	0.63	0.73	0.59	0.74	0.71
OT37	ACTTTtCTGcctcCaATACCTTGG	chr3:70299910+70300073	1.19	0.88	1.00	0.76	1.06	0.86
OT38	ACTTTGCT-CCACAATgCCTGGG	chr1:227324114-227324224	0.50	0.56	0.48	0.50	0.57	0.48
OT39	ACTTTGCTGCCACTgGTACCTGGG	chr4:20389722-20389855	0.62	0.52	0.53	0.51	1.02	0.48
OT40	ACTcTGCT-CCACAATAtCTGGG	chr4:101789193-101789357	0.58	0.64	0.56	0.69	0.64	0.66
OT41	tCTTTGCT-CCACAATAtCTGGG	chr4:129408329+129408552	0.74	0.91	0.87	0.81	0.96	1.04
OT42	ACTTgGCTGCCACA-ACCTGGG	chr18:23806155+23806259	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT43	ACTTTGCTG-CACcAATACCTGGC	chr1:70805762-70805954	0.57	0.55	0.53	0.61	0.53	0.50
OT44	ACTTTGCTGCCAC-ATACCaTGT	chr1:216169709+216169886	0.51	0.50	0.51	0.78	0.47	0.65
OT45	AC-TTGCTGCCAAaATgCCTTGG	chr5:52278218-52278389	0.66	0.96	0.67	0.59	0.68	0.60
OT46	ACTTTGCTTGCCAAaAATACCTGGA	chr5:59665136-59665275	0.45	0.50	0.47	1.43	0.51	0.51
OT47	ACTTTGCTGCC-CAAgAcTTGG	chr19:49082325+49082466	1.33	1.35	1.33	1.48	1.41	1.42
OT48	ACaTTGCTG-CAGaAATACCTTGG	chr12:50837080-50837226	0.79	0.77	0.67	0.72	0.76	0.75
OT49	AC-TgGCTGCCAcAATACCTGGG	chr12:79983294-79983445	1.22	0.85	0.83	0.88	0.86	0.74
OT50	ACTTT-CTGCCACatgACCTGGG	chr12:126286065-126286233	0.65	0.80	0.76	0.72	0.82	0.79
OT51	ACTTTGCTGatAC-ATACCTGGG	chr16:50829626+50829775	0.63	0.71	0.84	0.78	0.69	0.64
OT52	ACTTTGgTGCCAAcAATACCTGGG	chr16:67891109-67891286	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT53	ACcTTGCTG-CAGaAATACCTTGG	chr22:41811842+41811995	0.54	0.53	n.d.	0.48	0.69	0.46
OT54	ACTTCTGCTGcCACAaACCTTGG	chr8:10512237+10512356	0.56	0.42	0.43	0.44	0.45	0.48
OT55	ACTTaGCTGCCAgAA-ACCTTGG	chr8:130760741+130760888	0.40	0.41	n.d.	0.45	0.43	0.56
OT56	AC-TTGCTGCCACAATAcTTTG	chr14:93610395+93610551	0.65	0.48	0.70	0.55	0.49	0.58
OT57	AaTTTGCTGCCACAATt-CTAGG	chr10:20442761-20442922	0.51	0.50	0.52	0.49	0.46	0.53
OT58	ACTTTGCT-CCACAATACcAGG	chr11:58176050-58176199	0.80	0.76	0.67	0.78	0.81	0.92
OT59	tCTTTGCTGCCA-AtTACCTGGG	chr15:29093086+29093232	0.65	0.58	0.59	0.55	0.63	0.62
OT60	ACTTTGCTG-CAaAATACCTTGC	chr21:39088389+39088584	0.45	0.56	n.d.	0.49	0.46	0.61
OT61	ACcTTGCTGCCA-AAcACCTTGG	chr2:160662807-160662949	0.72	0.60	0.51	0.66	0.52	0.52

OT62	ACaTTGCTGgCACAAT-CCTGGG	chr2:213255950+213256111	0.65	0.57	0.52	0.87	0.54	0.55
OT63	ACTTTGgTtCC-CAATACCTGG	chr2:196036434-196036580	0.68	0.62	0.73	0.56	0.60	0.72
OT64	ACTcT-CTGCCACAATACCTAGA	chrY:13436340-13436535	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT65	ACTTTtCT-CCACAAtTACCTGG	chr6:39041870+39042064	0.56	0.75	0.50	0.59	0.82	0.73
OT66	ACcTTGCTG-CAgAATACCTGG	chr6:27785457+27785633	0.58	0.62	0.59	n.d.	0.67	0.65
OT67	AgTTTGTGCCACAA-ACCaAGG	chr6:9683015-9683167	0.47	0.57	0.67	0.60	0.57	n.d.
OT68	ACTTTGg-GCCAgAATACCTAGG	chrX:13570761-13570950	0.51	0.49	1.25	0.64	0.56	0.55
OT69	ACcTTGtTGCCA-AATACCTGG	chrX:48090226-48090407	0.62	0.64	0.71	0.81	0.65	0.75
OT70	AtTTTGCTGCCACAA-ACCaAGG	chrX:106057761-106057923	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT71	ACTgTGCTGCaACAA-ACCTGG	chrX:143235479-143235619	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT72	ACTTTGCT-CCACAATgCCTGGT	chr7:155177942+155178085	0.60	0.56	0.62	0.58	0.57	0.55
OT73	AC-TTgATGCCACAATACtTGGG	chr3:72392649-72392845	0.44	0.56	0.38	0.45	0.48	0.43
OT74	ACTcTGCTGCCACAgT-CCTAGG	chr3:133006042+133006198	0.48	0.40	0.44	0.51	0.31	n.d.
OT75	ACTcTGaTGCCACAGATACCTGGG	chr3:171524879+171525051	0.58	0.79	0.51	0.60	0.45	0.72
OT76	tCTTTGCT-CCACAATAtCTGGG	chr3:169677452-169677627	0.48	0.54	0.60	0.58	0.59	0.51
OT77	tCTTTGCTGCCAC--TACCTGG	chr1:184534886-184535019	0.91	0.86	0.99	0.99	0.69	0.80
OT78	ACTTTGCTGC--CAATACtTTGG	chr15:40233992+40234119	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT79	ACcTTGCTGCCAC--TACCTGGG	chr2:98883002-98883164	0.72	0.59	0.62	0.74	0.65	0.63

<sup>a</sup>The *PAH* on-target sequence and top ONE-seq-nominated and in-silico-nominated candidate off-target sequences with mismatched positions and bulges indicated by lower case letters and dashes.

<sup>b</sup>Coordinates in the GRCh38/hg38 assembly of the human genome; “+” and “-” indicate forward or reverse orientation of protospacer/PAM sequence.

<sup>c</sup>n.d. = PCR was unsuccessful for the genomic site.